FDA, CMS Memorandum Of Understanding Draft Circulating At Staff Level
This article was originally published in The Gray Sheet
Executive Summary
FDA approval timeframes for breakthrough technology could be shortened by leveraging Medicare claims data for postmarket surveillance, according to CMS Chief Medical Officer Sean Tunis, MD
You may also be interested in...
FDA And CMS Missions Converge In The Postmarket Arena – FDA’s Gottlieb
Development of postmarket studies represents the best opportunity for CMS and FDA to collaborate and streamline the regulatory and reimbursement process, according to FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD
FDA And CMS Missions Converge In The Postmarket Arena – FDA’s Gottlieb
Development of postmarket studies represents the best opportunity for CMS and FDA to collaborate and streamline the regulatory and reimbursement process, according to FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD
Wound Care Reimbursement Reforms Top AdvaMed “Sector” Wish List
Obtaining improved Medicare coverage and coding policies for wound care products will be an objective of a new "sector" being developed by AdvaMed